by Sermonix Pharmaceuticals | Jun 8, 2022 | News
Guiding Researchers and Advocates to Scientific Partnerships (GRASP) launched in 2019 to unite patient advocates, physicians and researchers through meaningful discussions of cancer-related topics Sermonix’s poster detailing the Phase 2 trial of lasofoxifene, its lead...
by Sermonix Pharmaceuticals | Jun 1, 2022 | News
COLUMBUS, Ohio, May 31, 2022 (GLOBE NEWSWIRE) — Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat ESR1-mutated metastatic breast and gynecological cancers, today announced two abstracts...
by Sermonix Pharmaceuticals | Apr 28, 2022 | News
COLUMBUS, Ohio, April 28, 2022 — Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat ESR1-mutated metastatic breast and gynecological cancers, today announced two abstracts accepted for...
by Sermonix Pharmaceuticals | Feb 24, 2022 | News
February 07, 2022 06:30am EST | Source: Sermonix Pharmaceuticals LLC A Columbus pharmaceutical startup has raised $40 million toward a drug that could slow progression of a type of treatment-resistant metastatic breast cancer – all because a grad student at...
by Sermonix Pharmaceuticals | Dec 13, 2021 | News
Poster describes pre-clinical findings that lasofoxifene alone or in combination with a CDK inhibitor may limit tumor progression in aromatase inhibitor (AI) resistant tumors not resistant due to an ESR1 mutation December 13, 2021 10:00 ET | Source: Sermonix...
Recent Comments